Regardless, the preclinical data strongly suggest that any impact of PTH or PTHrP analogs on tumor progression, whether positive or negative, is likely to be mediated entirely through its paracrine effects on the bone microenvironment. The gene discussed is PTH; the disease is neoplasm.